JPMorgan lines up a $45 price target on Vivus (VVUS) in the wake of the company's FDA panel...

|By:, SA News Editor

JPMorgan lines up a $45 price target on Vivus (VVUS) in the wake of the company's FDA panel recommendation for approval for its weight-loss drug. Analysts with the firm keep an Overweight rating in place, saying "we would still be buyers here given the magnitude of the vote." Shares +115.7% premarket to $22.75.